PRFX Stock Forecast: PRF Technologies Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores PRF Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (27): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (0): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PRFX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PRFX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Oct 2024 | Maxim Group | Downgrade | Hold | — |
| 26 June 2024 | Maxim Group | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
PRFX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PRFX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 53.7×
- Price / book
- 0.1×
- EV / EBITDA
- —
Cheaper than 4% of US stocks
Cheaper than 96% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −45.3%
- Return on assets
- −21.9%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PRF Technologies Ltd. has a market value of $1.7M.
Revenue in the twelve months to 30 June 2024: $0.0.
Net income over the same four quarters: −$17.7M.
Free cash flow in the twelve months to 30 June 2024: −$11.4M, after $21K of capital spending.
PRF Technologies Ltd. employs 6 people.
Data provided by Twelve Data
PRFX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PRFX’s peer groups, ranked by the model: utility stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own PRF Technologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PRFX
How does Ticker Nerd's model rank PRFX?
As at 21 Nov 2026, PRF Technologies Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (27 of 100).
What is the PRFX stock forecast for 2030?
No analyst covering PRF Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRFX are extrapolating price history, which says nothing about the business.
What does PRF Technologies Ltd. do?
PRF Technologies Ltd. is a specialty pharmaceutical company focused on reformulating established therapeutics for clinical use. Its current portfolio centers on post-surgical pain management and localized drug-delivery solutions, including PRF-110, an oil-based formulation designed for direct application into the surgical wound bed to provide sustained analgesia, and OcuRing-K, a bio-erodible implant developed for use in cataract surgery.
About PRF Technologies Ltd.
PRF Technologies Ltd. is a specialty pharmaceutical company focused on reformulating established therapeutics for clinical use. Its current portfolio centers on post-surgical pain management and localized drug-delivery solutions, including PRF-110, an oil-based formulation designed for direct application into the surgical wound bed to provide sustained analgesia, and OcuRing-K, a bio-erodible implant developed for use in cataract surgery. The company operates in the healthcare sector with an emphasis on developing proprietary treatment options that target specific surgical settings and recovery needs. Headquartered in Tel Aviv, Israel, PRF Technologies also maintains activity in advanced drug-delivery technologies, supporting its role as a niche player in specialty therapeutics and perioperative care.
CEO Mr. Efraim Cohen-Arazi · 6 employees · Israel · https://www.painreform.com